Pashtoon Kasi, Medical Director at City of Hope, shared on LinkedIn:
“Hot off the press!
KRAS Vaccine for patients with RAS+ cancers.
Benefit → durable.
More to come with the randomized study!
Opens to doors to off the shelf vaccine for so many patients with KRAS/NRAS mutations.”
Title: Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results
Journal: Nature Medicine
Authors: Zev A. Wainberg, Colin D. Weekes, Muhammad Furqan, Pashtoon M. Kasi, Craig E. Devoe, Alexis D. Leal, Vincent Chung, James R. Perry, Thian Kheoh, Lisa K. McNeil, Esther Welkowsky, Peter C. DeMuth, Christopher M. Haqq, Shubham Pant, Eileen M. O’Reilly
More posts featuring Pashtoon Kasi on OncoDaily.